QRGenetics
AI-based Drug Discovery Engine for Genetic Diseases
Company Overview
Snapshot
Founded in June 2019 by Shane Wald-Altman, Dan Lavi, and Miguel Weil, QRGenetics operates with 1–10 employees. The company received a grant in December 2023 from Israel Investment Partners (IIP), marking a key milestone in its development.
Business overview
QRGenetics develops an AI-supported drug discovery engine focused on identifying potential therapies for common genetic diseases. The platform utilizes exclusive spatial analytics and proprietary omics datasets to uncover novel drug-target combinations, including new applications for drugs nearing patent expiration. The company primarily serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically in Drugs Discovery & Development.
Strategic signal
In December 2022, QRGenetics was highlighted for its AI-powered platform designed to rapidly diagnose genetic mutations and predict suitable drug or natural substance treatments. This development is significant as it addresses the critical need for accelerated and personalized treatment solutions for rare genetic diseases, indicating strong potential for growth and expansion into patient care.
Log in to access full profile ›Company Intelligence Q&A
- What is QRGenetics' core technology?
- QRGenetics utilizes an AI-supported drug discovery engine that incorporates exclusive spatial analytics and proprietary omics datasets. This technology is designed to rapidly identify novel drug-target combinations for various indications.
- When was QRGenetics founded and by whom?
- QRGenetics was founded in June 2019 by Shane Wald-Altman, Dan Lavi, and Miguel Weil.
- What significant non-equity funding did QRGenetics receive?
- In December 2023, QRGenetics received a grant from Israel Investment Partners (IIP).
- What was QRGenetics' involvement with Microsoft for Startups?
- QRGenetics graduated from the 'AI for Good - Microsoft for Startups' corporate accelerator program in April 2022, completing batch 3 of the program in July 2022.
- What are QRGenetics' plans for patient treatment expansion?
- In December 2022, QRGenetics announced plans to treat 50 patients from Israel in the subsequent year, with an aim to expand to 500 patients from Israel and other countries in the year following that.